Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 2/4/20 → 6/2/25 |
Funding
- Merck Sharp & Dohme Corporation: $158,924.00
Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
- Arnold, Susanne (PI)